R-Pharm plans to introduce three drugs for the treatment of oncological diseases to the Russian market. The results of recent trials for the experimental therapies were presented at the XXIX Russian Oncological Congress, the pharmaceutical manufacturer’s press service told GxP News.
Two of the drugs – biosimilars of pertuzumab and cetuximab – are in the final stage of clinical development, with their registration expected in 2026.
Pertuzumab is a monoclonal antibody intended for the therapy of HER2-positive breast cancer, one of the most aggressive types of this disease. Cetuximab is also a monoclonal antibody, used, among other things, in the treatment of head and neck tumors. Both drugs have completed Phase III clinical trials, during which they “demonstrated efficacy not inferior to the original molecules and comparable safety profiles.”
“Pertuzumab is included in the most effective treatment regimen for HER2-positive metastatic breast cancer, allowing for increased life expectancy in this challenging patient group. The emergence of new biosimilars enhances the accessibility of advanced therapeutic combinations for Russian healthcare,” noted Tatiana Dergacheva, Director of the Medical Support Department for Oncology Products at the company.
The third candidate, R-Pharm’s original drug RS-113, a next-generation antiandrogen, is undergoing Phase II clinical trials for the treatment of metastatic prostate cancer. Based on the results of 6 months of trials, RS-113 confirmed efficacy comparable to abiraterone – the standard therapy for this type of cancer. Furthermore, the drug shows a tendency towards a more favorable safety profile, the company emphasized.
The XXIX Russian Oncological Congress with international participation took place in Moscow from December 11 to 13, 2025. The largest national event dedicated to the cancer diagnosis, treatment, and prevention was organized by the Russian Society of Clinical Oncology, the N.N. Blokhin National Medical Research Center of Oncology, and the Association of Oncologists of Russia. The event was attended in person and online by over 20,000 people.
